Peptonic Medical AB - in the early stages of a mission to improve women's lives

[Old_man]

Peptonic signs distribution agreement with German Medical Supplies for UAE

THU, SEP 01, 2022

Peptonic Medical (publ) today announced that the company has signed a non-exclusive distribution agreement with German Medical Supplies for the United Arab Emirate market. The agreement concerns Peptonic’s patented self-test to identify amniotic leakage.

Peptonic Medical has during the pandemic observed a growing trend where people want to take greater ownership concerning their own health. This by using self-care solutions contributing to a reduced pressure on health care systems. It is important for users that these self-care solutions are clinically proven.

To meet this trend Peptonic has formed the business unit Medical Consumer. The purpose is to build a unique portfolio that enables women to diagnose, treat and prevent vaginal health issues with clinically proven self-care solutions. The acquisition of Israeli company CommonSense, specialists in vaginal self-tests, at the end of 2021, was an important step

The new business unit is growing rapidly and attracts new partners. Today Peptonic announced it has signed a distribution agreement with German Medical Supplies for distribution and marketing of Peptonic’s patented self-test to identify amniotic leakage during latter parts of pregnancies. The agreement is for the United Arab Emirate and is non-exclusive. German Medical Supplies will sell the product under its own brand name Amnitec Plus™.

German Medical Supplies import and distribute high quality medical devices to UAE. Peptonic’s self-test to identify amniotic leakage is now added to the portfolio. The product has been registered with UAE’s medical device authorities and will be launched during the fall.

What does this mean in practice? An opportunity for this company to get products on sale in new areas, or will it be buried in complete silence at some point? It feels like they are trying hard, but the continuous losses should stop at some point.

[Torniojaws]

@Old_man

What does this mean in practice? An opportunity for this company to sell products in new areas, or will it be silently buried at some point? It seems like they are trying hard, but the continuous losses should stop at some point.

Yeah, things have stalled a bit. Sales have been ongoing in the USA and Japan for quite some time, and they even sold in China for a while until that distributor started having problems, but nothing much has really shown up on the bottom line.

[Old_man]

Peptonic is in an expansion phase, and revenue is growing at a good pace. Profitability is delayed, and our forecasts include additional financing needs.

Increased Revenue in the First Half of 2022

Peptonic Medical increased its revenue by 13% in H1 2022 to SEK 21.3 million. The operating profit for the period amounted to SEK -19.0 million. In Q2, both sales and results improved significantly, both compared to Q2 2021 and Q1 2022. The positive sales development is primarily explained by the positive development of vaginal self-tests for international license partners in the USA and Europe. There has also been a continued positive development for its own brand VagiVital in the Swedish home market. As in Q1, the home market contributed positively to the result in Q2.

Acquisition of Israeli CommonSense is Developing Well

Peptonic’s new strategy with clinically proven self-care based on the principle of diagnose-treat-prevent meets a strong societal trend reflected in growing sales and a strong order book. The focus during H1 2022 has been on incorporating the acquired Israeli CommonSense and the products within patented vaginal self-diagnostics that came with it. In the USA, important OEM customers such as Walgreens, CVS, and Exeltis have been secured for CommonSense during H1. The lower gross margin, which was 51% in Q2, is due to an increased share of sales to international license partners with higher volumes but lower margins. Renegotiated prices for CommonSense’s products and efficiency improvements in production are expected to have a positive impact on the gross margin. For the wholly-owned subsidiary Lune in Finland, sales during H1 have been below expectations due to hardening competition. Going forward, the company will focus on better meeting increasing competition by targeting fewer markets, including Finland, Sweden, and Australia.

Target Price Adjusted to Account for Capital Needs

Peptonic is in an expansion phase and is expected to be profitable from 2025. As the company communicated in its Q1 report, there are additional future financing needs. We are adjusting our valuation model to account for this and also adjusting our sales forecast for 2022 to SEK 43 million (previously 60). Our new target price for Peptonic in our base scenario is SEK 0.90 (previously 1.30).

Short, informal Finnish translation: Peptonic is a company in a growth phase, expected to be profitable in 2025.

Additional financing needs are reportedly present. Will it be a share issue, or can financing be arranged from elsewhere?

Sales of Lunette menstrual cups have been weaker than expected, and they will now focus only on Finland, Sweden, and Australia.

The acquisition of CommonSense is progressing well.

Sales of vaginal diagnostic kits (or whatever they are?) have developed positively in the US and Europe. Is the sale under their own brand, or not? The story doesn’t say, but presumably not under their own brand, as they mention that the development of their own VagiVital brand has been positive.

[Old_man]

@Sijoittaja-alokas, have you at some point praised this stock? You’re often mentioned in the investment meme thread as being responsible for the collapse of various stock prices, so I wondered if you were behind this result?

Down 68% in a year, this small trial purchase is going to waste.
Why Sijoittaja-alokas specifically? According to the meme thread, when that username praises a stock, its price drops.

[Torniojaws]

The reason for the drop seems to be non-existent sales, even with FDA approvals and all. No one is buying, even though it’s available. Maybe they should invest in marketing elsewhere than just Sweden

[Old_man]

PEPTONIC Medical AB: INTERIM REPORT Period from January - September 2022

10.11.2022 10.25 • Cision •

Kopioi linkki leikepöydälle

Peptonic Medical AB (publ) org nr 556776-3064

(www.spotlightstockmarket.com, ticker: PMED)

GROUP

2022 THIRD QUARTER (Jul-Sep)

• Net sales of products KSEK 12 180 (7 234)

• Gross profit KSEK 7 137 (4 492), Gross margin 59% (62%)

• Operating loss KSEK -7 786 (-9 856)

• Adjusted operation loss excl. non-recurrent charge KSEK -7 286 (-9 856)

• Loss per share SEK -0,04 (-0,05)

2022 FIRST NINE MONTHS (Jan-Sep)

• Net sales of products KSEK 33 442 (25 948)

• Gross profit KSEK 19 002 (16 061), Gross margin 57% (62%)

• Operating loss KSEK -26 807 (-28 780)

• Adjusted operation loss excl. non-recurrent charge KSEK -26 307 (-28 780)

• Loss per share SEK -0,12 (-0,15)

From the CEO

Second consecutive quarter with improved result

For the second quarter in a row, results are improved. Key underlying reasons are continued positive sales development of the company’s vaginal self-tests to partners in the US and Europe, as well as the work to focus Lunette efforts in fewer markets.

Sales compared to previous quarter are largely unchanged (ca -1.5%) where quarter two also contained a batch order to Orion.

The third quarter result is negatively affected by a reservation of 0.5 MSEK related to a potential penalty the Swedish Ecocrime Authority has announced due to a financing solution in 2019. The penalty aside the bottom line improves 10% compared to previous quarter.

Business Unit Medical Consumer - New products are well received

During the pandemic Peptonic has observed a growing trend where people want to take a greater responsibility for their own health. This by using self-care products. In parallel also reduce pressure on health care systems. An important aspect is then that these self-care products have to be clinically proven.

As a result Peptonic has formed the Business Unit Medical Consumer. The purpose with the unit is to establish a portfolio the enables women to diagnose, treat and prevent vaginal medical conditions with clinically self-care solutions. The acquisition of Israeli CommonSense was an important step to start forming the business unit.

During the quarter Peptonic has presented its patented self-test to detect amniotic lakage during pregnancy at the Swedish Association of Gynecologists annual meeting SFOG. The product was well received as a correlating option does not exist in health care today. During the fall, winter and spring mid wives and gynecologists will be educated concerning the benefits and clinical plat form related to the product. The self-test to detect amniotic leakage, VagiVital AL, has during the quarter been listed for sales in Swedish digital pharmacies.

The interest from international partners concerning VagiVital AL is significant. New distributor agreements have during the quarter been signed with German Medical Supplies for UAE and InVivo Pharma for Georgia. A renewed distributor agreement with Primalabs concerning Italy, France, Poland, Hungary and Romania has also been signed during the quarter.

Peptonics vaginal self-tests as a whole attract many inquiries from potential international distributors.

The development work to broaden the portfolio in line with the newly set strategy is on going. The clinical study with an adapted version of VagiVital AktivGel for the treatment of vaginal yeast infections is still ongoing at the Karolinska University Hospital. The study is expected to be finalized during 2023. We have also informed the market that the submitted patent application for the adapted gel in this indication has passed international assessment. The same applies to the original gel for the treatment of vestibulitis. The company is currently assessing how this shall be taken to the market in the best way.

Business unit Medical Consumer sales in the quarter equaled 6.9 MSEK. The majority of this sales was from sales of the vaginal self-tests.

Business Unit Lifestyle Consumer - Improved Focus gives improved direction

The company’s wholly owned subsidiary Lune Group with its sustainable period products as core business, constitutes Peptonics other more life style oriented business unit.

During the spring a renewed strategy was set where Lune reduces its cost mass and focuses on fewer markets. The objective with the revised strategy is to increase competitiveness in selected markets thereby improving results. Amongst focus markets are Finland, Sweden and Australia. The increased focus has started to pay off and the negative result has started to significantly improve in the quarter.

The improved focus is multi-dimensional. Most of Lune business arises from sustainable period products. The renewed focus also means renewed focus and efforts around these core products. During the quarter Lune’s new reusable period panties has been picked up for sales a by a major Finnish retail chain as well as a global Swedish retail chain.

Business unit Lifestyle Consumer sales during the quarter correlates to 5.3 MEK.

The new strategy and focus - a foundation for continuous positive development

Concerning vaginal medical conditions one can, a bit simplified, say that there are prescription products and self-care products. Peptonics objective is to create a new category with clinically proven intimate self-care products. The aim is to become a leading player in this category by offering innovative complete solutions that enable diagnose, treatment and prevention of the medical conditions that occur.

With the distinct profile, the attractiveness of the vaginal self-tests as door openers and new innovative products in line with the strategy, Peptonic expects continuously increased distribution in Swedish pharmacies as well with international distributor partners.

With the above as platform the company shall continue broadening the portfolio through a combination of own development, in licensing and acquisitions.

November 10, 2022

All in all,
this company is still operating at a loss.
However, they did not mention the possibility of financing through new share issues this time. Why? Do they just not want to repeat what was said in the previous interim report, or do they have an external financier?

At least net sales have increased (compared to the previous quarter, or compared to a year ago?), and margins seem to be in order. More sales are just needed to turn a profit.

They have started selling period underwear. They boast that a major Finnish retailer and a global Swedish retailer have added them to their selection. Unfortunately, brands like Libresse are also active in the same market, and the latter is a more well-known brand.

Let’s see what happens. Will this small company become profitable and in what timeframe, or what will its fate be? Time will tell.

[jokuvaan1]

I sold the company’s shares at the beginning of the year because I concluded that the company’s products are good but not sufficiently unique or critical to anyone.

So, even at this valuation level (under 7 million euros), I wouldn’t get back in, because Sweden is full of Biotech companies with a similar market cap, but whose products, once developed, are unique/critical for many patients.

Of course, one can make a profit if one correctly predicts/guesses the “turnaround moment” when the share price starts to rise again as business performance improves.

[Old_man]

Peptonic Medical (publ) announced today that Lena Munkhammar has requested to resign from Peptonic Medical’s board of directors.

Lena joined Peptonic Medical’s board at the annual general meeting on May 24th of this year. Lena has chosen to step down from the board and justifies her decision by stating that her experience and expertise are not what the board currently needs.

Peptonic thanks Lena for her dedicated and active work for the company.

In brief in Finnish: Lena Munkhammar resigns from Peptonic’s board. Lena states as the reason that her experience and skills are not at the level the board needs.

Well, well. Did someone wisely abandon a sinking ship, or what is the reason? Let’s see what they find to replace her.

[Old_man]

Peptonic Medical (publ) informed today that it’s wholly owned subsidiary Lune Group Oy has won the Klarna Growth Award in the category “Small Business”

Lunette was selected from a group of over 300 nominees from Finland alongside Oura, Weekendbee and Almada. In total there were 16 winners from 4 different countries. Prize contains total of 18 MSEK, which will be divided between the winners in terms of marketing support in Klarna channels.

“Early 2022 Lunette signed a long-term supplier agreement with UN and has a long history working on a mission to end period poverty, Lunette is a clear winner in the small business category.”, Klarna declares as part of their motivation.

In the Klarna Growth Awards, e-retailers from Sweden, Finland, Denmark and Norway were nominated in four categories:Sustainability, Rising Star, InnovationandSmall Business. The prizes consist of tailor-made growth packages worth approximately 18 SEK million in total, including annual subscriptions to the influencer marketing platform APPRL, Klarna’s comparison service Klarna Comparison Service (CSS), advertising in Klarna’s app and a unique opportunity to use Virtual Shopping ( formerly Hero) is included. The winners were chosen by the jury consisting of Country Lead,CMO David Sandström, Fashion Director Emilia de Poret and Head of Social Shopping Adam Levene.

• In recent years, we have done a great job of trying to understand where and how we can best help our traders achieve their goals. On the one hand, we now ensure that consumers, i.e. our retailers’ customers, are offered sustainable and decent payments, and on the other hand, we accelerate retailers’ growth with our marketing services. With the Klarna Growth Awards, we hope to inspire, engage and inform - and give traders optimal tools for growth,says Jesper Eriksson, Country Lead, Klarna Sweden.

“We are extremely proud of this award, and we are looking forward to accelerate our online business with new Klarna tools as well as spreading our vision of safe and sustainable periods to bigger audiences”, says Heli Kurjanen, founder and CEO of Lunette.

Erik Sundquist, CEO

Oh. Että oikein Klarnan palkinnon ovat voittaneet. No, jos tämä auttaa heitä saamaan tuotteilleen näkyvyyttä niin hyvä homma. En vain pidättele henkeäni sitä odotellessa.

[Alisuorittaja]

Peptonic’s board has made a conditional decision on a rights issue of approximately 68.0 million Swedish kronor

Nordnet

[Old_man]

It looks like they did just that, as I speculated earlier. Clearly, they weren’t able to secure an external financier for their operations. My small test purchase is going down the drain even more if the share price doesn’t turn around. No – I’m definitely not participating in the share issue, and the reason should be obvious. I might be wrong. After all, even Facebook dipped for a while after its IPO, but then it became a real bubble stock. In this case, I don’t believe in such a phenomenon. I’ll probably have to wait X years until I make a profit on some other stock so I can use this for tax deductions.

[Old_man]

The rights issue ended up raising 55.0 million kronor for Peptonic. They intend to use the funds for product portfolio development and sales promotion, etc.

Right. Hopefully, sales promotion also includes marketing. My small pilot position was worryingly diluted.

[Old_man]

This thread has turned into quite a monologue.

Two flagging notifications were issued regarding Peptonic:

Maida Vale Capital AB subscribed for 161,600,724 shares and owns 161,600,724 shares after the Share Issue. This corresponds to approximately 15.7 percent of Peptonic’s outstanding shares. Before the issue, Maida Vale Capital did not own any Peptonic shares.

Vidarstiftelsen subscribed for 80,628,568 shares and owns 149,778,054 shares after the Share Issue. This corresponds to approximately 14.6 percent of Peptonic’s total outstanding shares and votes. Before the Share Issue, Vidarstiftelsen owned 28.5 percent of Peptonic’s total outstanding shares and votes.

Now the question is: why? Has Maida Vale seen a diamond in the rough here that needs to be polished? They are unlikely to pour money into a small outfit like this just for fun.

And is Vidarstiftelsen losing faith in this investment? I haven’t managed to find any information on either company that sheds light on the mystery.

[Old_man]

Annual report released:

FULL YEAR 2022 (Jan-Dec)

• Net sales of products 43,634 (31,643) tkr

• Gross profit 23,394 (19,070) tkr, 54% (60%)

• Operating loss -33,606 (-73,718) tkr

• Loss per share -0.15 (-0.38) kr

The good thing is that sales have continued to grow.

They also boasted about obtaining new patents. Ok. However, it was not disclosed anywhere what has been patented and whether this will help increase product sales?

[Old_man]

Peptonic Medical (PMED:SS) today announced that it has signed a non-exclusive agreement with the medical technology company Siemens Healthineers for the distribution of Peptonic’s portfolio of diagnostic products for vaginal health.

The agreement with Siemens Healthineers is global and non-exclusive. It centers around Peptonic’s patented diagnostic products for vaginal health.

“This agreement is attractive from many aspects. We will get a very strong force in Siemens Healthineers that will help to raise awareness of the benefits of our unique and patented technology,” said Erik Sundquist, CEO of Peptonic Medical.

The agreement with Siemens Healthineers is expected to contribute positively to Peptonic’s revenues from 2024.

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care.

This disclosure contains information that PEPTONIC Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-04-2023 08:34 CET.

Tällainen uutinen tuli ulos tänään, ja kurssi on pompannut ylöspäin.
En pidättele henkeä tällaisen pikkufirman kohdalla. Tällä firmalla on ollut historiassaan kupruja sun muita tyrimisiä, joista voi lukea mm tästä ketjusta. Firman suunta vaikuttaa kuitenkin oikealta hiljalleen, mikä on pienomistajan kannalta aina iloinen asia.

[Old_man]

Peptonic Medical AB (publ) today announced that the company has signed an exclusive agreement with Cetro Medical for distribution of VagiVital VS Pro and VagiVital AL to gynecology and obstetrics clinics in Sweden.

The agreements means that Cetro Medical gets an exclusive right to sell VagiVital in the professional channel, i.e. to hospital and clinics. The agreement spans over three years with possible extension.

“In Cetro Medical we get a resourceful partner with a long and successful experience in distribution of products for gynecology and obstetrics. This is a partnership and a cooperation model that we are very much looking forward to develop”, says Erik Sundquist, CEO of Peptonic.

It further enables Peptonic to focus on its core business; clinically proven intimate self care according to the principle diagnose, treat, prevent. A user of Peptonics products shall be able to manage everything from identifying and treating the intimate health problem to preventive actions with products that prohibit the problems from returning.

Some of the products are excellent for distribution to different healthcare units;

• VagiVital VS Pro is a customized version of VagiVital VS, which we sell directly to consumers. VagiVital VS Pro enables healthcare professionals to screen for bacterial vaginosis with a unique combination of precision and immediate results.

This is to us an optimization of resources and business potential and a model that we intend to apply when we build our own brand globally in a cost- and resource-efficient way," says Erik Sundquist.

“Cetro Medical delivers innovative and gentle examinations and treatments. We see Peptonic’s care-adapted products as perfect additions to our portfolio and are in line with our current offering”, says Carlos Wilhemsson, CEO of Cetro Medical.

Uutta jakelusopimusta pukkaa? Katsotaan milloin, ja miten tällainen näkyy firman tuloksessa. Joskushan sen pitäisi näkyä.

[Old_man]

Peptonic Medical AB (publ) today announced that an arbitration court in China has ruled in favor of Peptonic in a dispute with Yuanjia Biotechnology Co., Ltd.

In November 2020 and February 2021, Peptonic Medical shipped goods to Yuanjia Bio in China for a total value of 406,000 EUR (approx. 4.4 MSEK). However, the goods were never paid for. As a result, Peptonic terminated the distribution agreement with Yuanjia Bio in August 2021 and filed an arbitration application against its former partner at a Chinese court. The court has now ruled in favor of Peptonic Medical and ordered Yuanjia Bio to settle the outstanding debt to Peptonic.

The arbitration procedure in China means that the local party becomes personally liable for debts or claims ruled by the court. This increases the likelihood that the defendant will accept the ruling and pay the outstanding debt.

“This is good news for us. However, we still need to collect the debt, but with the court ruling in our favor, our chances of success increase significantly. This is an important victory since it also shows we can defend Peptonic’s properties in challenging situations,” said Erik Sundquist, CEO of Peptonic Medical

Peptonic has won a legal case in China. The local party had left delivered goods unpaid and Peptonic had taken the matter to an arbitration court. Now Yuanjia Bio has been ordered to pay the bill. Of course, whether they will actually pay is another matter. Time will tell. And will Peptonic continue to cooperate with a company from which receivables must be collected through an arbitration court?

[Old_man]

2023-06-15 13:00:00 - Cision International
PEPTONIC Medical AB : Peptonic and Pharmiva sign letter of intent to merge and create a leading intimate women’s health company
The FemTech companies PEPTONIC medical AB (“Peptonic”), listed on Spotlight Stock Market, and Pharmiva AB (publ) (“Pharmiva”), listed on Nasdaq First North
Growth Market, have signed a letter of intent with the intention of combining the companies through a planned merger (the “Letter of Intent”).

The Boards of Directors of Peptonic and Pharmiva (together the “Companies”) have signed a letter of intent to clarify the Companies intention regarding a merger
of Peptonic and Pharmiva. The joining of the two companies is planned to be completed through a merger under Swedish company law (the “Merger”). The completion
of the Merger is conditional upon, inter alia, that the Boards of Directors of each company resolve to complete the Merger and that the Merger is approved by an
extraordinary general meeting in Pharmiva. The final decision on the merger will be made after union negotiations have been completed.

According to the Letter of Intent, the ownership in the joint venture shall, indicatively, correspond to the following:

(a) Peptonic’s holding is intended to amount to eighty-five (85) percent of the number of shares in New Peptonic.

(b) Pharmiva’s holding is intended to amount to fifteen (15) percent of the number of shares in New Peptonic.

In order to carry out the distribution as above, the Company’s intention is, indicatively, that shareholders in Pharmiva shall receive [twelve (12)] shares in
Peptonic for each one (1) share owned in Pharmiva in the form of merger consideration. However, the final merger consideration will be determined after the
Companies have prepared and adopted a joint merger plan for the Merger.

The planned Merger in brief

· The merger is intended to be carried out by Peptonic absorbing Pharmiva, which will subsequently be dissolved.
· The proposed merger requires, among other things, that the Companies’ boards of directors resolve to adopt a joint merger plan and that the Merger is
approved by an extraordinary general meeting of Pharmiva. No final decision on the merger will be made until the union negotiations have been completed.
· Declarations have been made with shareholders of Pharmiva regarding the contemplated Merger, and shareholders representing more than 37 percent of the
shares in Pharmiva have undertaken or given their intention to vote in favour of the proposed Merger at an extraordinary general meeting, provided that the
other conditions for completion of the Merger are fulfilled.
· The completion of the Merger will not be dependent on any financing as the Merger Consideration will consist exclusively of new shares in Peptonic.
· More information about the Merger and the merger plan is expected to be published around the week 27 2023
· A merger document is expected to be published around week 29 2023.

Allekirjoittaneelle tämä tieto tuli puskista. Pharmivaa en myöskään tiedä entuudestaan. Seuraan mielenkiinnolla, mitä tämä fuusio tuo tullessaan.

[Old_man]

Peptonic Medical AB (publ) today announces that the Stockholm District Court has rejected the Swedish Economic Crime Authority’s (EBM) claim for a corporate fine for Peptonic of SEK 500,000.

The judgment relates to the investigation of serious insider crime that Peptonic previously informed about and which are related to measures taken by the company within the framework of a financing arrangement between the company and a financial actor in the spring of 2019. At the beginning of 2022, Peptonic was informed that EBM intended to claim a corporate fine for Peptonic of SEK 500,000 due to the investigation. EBM reiterated its claim in September 2022 in connection with the former chairman, CEO and CFO of the company being charged with serious insider crime. According to the judgment from the District Court, the accused persons and the company are now acquitted on all counts.

Peptonic reserved an amount corresponding to the corporate fine in its third quarter 2022 results. Peptonic intends to decide to dissolve the reserve in connection with results for the second quarter of 2023.

Google translate vomit
Peptonic Medical AB (publ) announced today that the Stockholm District Court has rejected the Swedish Economic Crime Authority’s (EBM) demand for a corporate fine of SEK 500,000 for Peptonic.

The judgment concerns the investigation into serious insider crime previously reported by Peptonic, which relates to measures taken by the company in the spring of 2019 within the framework of a financing arrangement between the company and a financial actor. At the beginning of 2022, Peptonic was informed that EBM intended to demand a SEK 500,000 corporate fine for Peptonic due to the investigation. EBM reiterated its demand in September 2022 when the company’s former chairman, CEO, and CFO were charged with serious insider crime. According to the District Court’s judgment, the accused and the company have now been acquitted of all charges.

Peptonic reserved an amount corresponding to the corporate fine in its third-quarter 2022 results. Peptonic intends to decide on the reversal of the reserve in connection with the results for the second quarter of 2023.

So the charges have been dismissed. I wonder if they will take these employees back now?

[Old_man]

Peptonic Medical AB (publ) (“Peptonic”) announced today that the company has agreed with the world’s largest retail chain Walmart to begin selling Peptonic’s self-test for bacterial vaginosis.

The US is an important market. It is very gratifying that Walmart has decided to sell our patented self-test for bacterial vaginosis," says Erik Sundquist, CEO of Peptonic Medical.

“Increasing the distribution of our products is an important part of our strategy, which makes this agreement with the world’s largest retail chain Walmart extra positive and also shows that the need for our products is great. It paves the way for rapid growth in what is already our largest market today,” says Erik Sundquist.

The distribution agreement with Walmart, which has approximately 10,500 stores worldwide, of which just under 5,000 are in the United States, primarily applies to Peptonic’s patented self-test for diagnosing bacterial vaginosis. The test will be sold under Walmart’s own brand. What makes the test unique is the combination of high precision and immediate results.

The distribution agreement applies to the United States and Walmart is now conducting an overview of stores currently for distribution.

In Peptonic’s American organization, since the beginning of summer 2023, Angella Garcia is responsible for retail chains. Angella has extensive experience in sales to these channels in the US, but also in medtech. Through the agreement with Walmart, there is also a dialogue about the distribution of a further selection of Peptonic’s current and future products. Pharmiva’s product Vernivia will be an excellent and unique treatment solution for the self-test for bacterial vaginosis.

Peptonic expects the agreement to have a positive impact on the company’s sales from 2024.

Jaa että uusi jakelusopimus. Kuulostaa hyvältä, mutta menevätkö tuotteet kaupaksi loppuasiakkaille?
Entä paljonko tuotteille saadaan katetta?

En oikein pääse kärrylle kokonaisuudesta.
Siemens myy Pepin tuotteita, Walmart myy samoja tuotteita. Kilpailevatko Pepin tuotteet toisiaan vastaan kahden eri jakelijan välillä?
Entä miten pakkaa sekottaa fuusioituminen Pharmivan kanssa? Toteutuuko voitollinen tulos vuonna 2024? Pohdittavaa riittää. Lisäsin hieman Pepiä salkkuuni kruunun edullisen kurssin vuoksi.